L Capital Partners

News, insights, analysis and data

← Back to L Capital Partners profile

L Capital Partners related stories

All articles and analysis

  • IPO Profiles, April 2010
    Staff Writer- 1 June 2010

    Seven VC-backed companies went public in April: Alimera Sciences, Alpha & Omega Semiconductor, Codexis, Convio, Global Geophysical Services, SPS Commerce and Tengion

  • Tengion Raises Low IPO
    VCJ Staff- 12 April 2010
  • peHUB Wire: Monday, April 12, 2010
    Brad Meikle- 12 April 2010

    Random Ramblings

  • peHUB Wire: Monday, April 12, 2010
    Brad Meikle- 12 April 2010

    Random Ramblings

  • Tengion Sets IPO Terms
    VCJ Staff- 17 March 2010
  • peHUB Wire: Wednesday, 17, 2010
    Brad Meikle- 17 March 2010
  • peHUB Wire: Wednesday, 17, 2010
    Brad Meikle- 17 March 2010
  • VCs Stuff More Companies Into IPO Pipeline
    Dan Primack- 16 March 2010

    Financial Engines priced its IPO above range last night, and just closed its first day of trading up nearly 44 percent. It was the fifth VC-backed IPO to price in 2010, and the third to do so since we last looked at the VC-backed IPO pipeline /63772/vc-backed-ipo-pipeline-fills-up/ (the others were pharma companies AVEO and Anthera). There also have been four new additions to the pipeline in the past month, including the recent filing from Broadsoft. That works out to a net total of 38 VC-backed companies in registration to go public on U.S. exchanges, representing more than $4.5 billion in targeted raise. View the entire pipeline after the jump...

  • Tengion Increases IPO Expectations
    VCJ Staff- 25 February 2010

    Tengion Inc., an East Norriton, Penn.-based regenerative medicine company focused on replacement organs like bladders, has raised the target for its IPO from $40.25 million to $46 million. It also has added Leerink Swann as a co-lead underwriter, alongside Piper Jaffray. Tengion has raised over $140 million in VC funding, from Oak Investment Partners (19.6% pre-IPO stake), HealthCap (14.3%) Johnson & Johnson Development Corp. (12.5%), Brookside Capital (8.6%), Bain Capital Ventures (8.5%), Quaker BioVentures (8.3%), L Capital Partners (6.4%), Deerfield Partners and Safeguard Scientifics. www.tengion.com

  • peHUB Wire: Thursday, February 25, 2010
    Brad Meikle- 25 February 2010

    Random Ramblings